Logo
Logo

About Quetiapine Fumarate API

Product
  • Therapeutic CategoryCentral Nervous System (CNS)

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, EUDMF, Canada DMF, Korea DMF, China DMF, Japan DMF

Mechanism of Action

"The mechanism of action of SEROQUEL is unknown. However, it has been proposed that the efficacy of SEROQUEL in schizophrenia and its mood stabilizing properties in bipolar depression and mania are mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other effects of SEROQUEL. SEROQUEL’s antagonism of histamine H1 receptors may explain the somnolence observed with this drug. SEROQUEL’s antagonism of adrenergic α1 receptors may explain the orthostatic hypotension observed with this drug."

Indication

SEROQUEL is an atypical antipsychotic indicated for the treatment of:

  • Schizophrenia
  • Bipolar I disorder manic episodes
  • Bipolar disorder, depressive episodes

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Quetiapine Fumarate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Quetiapine Fumarate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

FAQs

What is Quetiapine Fumarate API used for?
  • Treats schizophrenia, bipolar disorder, and major depressive disorder

What are the benefits of Quetiapine Fumarate API?
  • Reduces psychotic, manic, and depressive episodes
    Helps restore balance of serotonin and dopamine

What is the safety guide for Quetiapine Fumarate API?
  • Avoid inhalation and skin contact
    Use protective equipment
    Store in a cool, dry place, away from light

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.